+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
HAE Treatments Market - Global Forecast 2025-2030- Product Image
HAE Treatments Market - Global Forecast 2025-2030- Product Image
Sale

HAE Treatments Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6119217
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Hereditary angioedema is a challenging, potentially life-threatening disorder that demands continuous adaptation and innovation across the biopharmaceutical supply chain. This market is evolving rapidly, shaped by advances in drug modalities, regulatory developments, and shifting reimbursement strategies. Senior decision-makers are navigating complex treatment pathways and leveraging digital health solutions to ensure delivery of innovative and accessible care.

Market Snapshot: Hereditary Angioedema Treatment Landscape

The hereditary angioedema market is gaining momentum, underpinned by a growing pipeline of targeted therapies, novel administration routes, and increased investment in patient-centric solutions. Market size and CAGR are driving strategic planning across companies, payers, and providers committed to delivering next-generation therapies and operational excellence. As patient needs and preferences diversify, market participants are differentiating through value-based contracting, robust real-world evidence, and adaptive pricing models, fostering a resilient competitive landscape.

Scope & Segmentation

This research provides detailed segmentation and analysis across all critical vectors, including mechanisms of action, product innovations, administration routes, and geographic nuances. These layers offer a comprehensive view of the hereditary angioedema treatment market, enabling stakeholders to align commercial strategies with evolving demand.

  • Therapy Mechanisms: Bradykinin receptor antagonists (including future oral candidates, icatibant), C1 inhibitor replacement (plasma-derived, recombinant analogs, gene therapies, monoclonal antibody therapies), kallikrein inhibitors (ecallantide, lanadelumab, catalytic inhibitors under evaluation).
  • Product Types: On-demand treatments, prophylactic regimens, extended half-life therapies, long-acting prophylactics.
  • Routes of Administration: Intravenous, subcutaneous, and oral modalities focused on enhancing self-administration and adherence.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, specialty pharmacies, direct-to-patient delivery models.
  • End Users: Hospitals, clinics, home healthcare environments, and telemedicine platforms.
  • Patient Age Groups: Adults, pediatrics, geriatrics, and emerging adolescent segments requiring tailored dosing protocols.
  • Regional Coverage: Americas (including the United States with subnational states), Europe, Middle East, Africa, and Asia-Pacific, reporting diverse infrastructure and adoption patterns.
  • Company Coverage: Takeda Pharmaceutical Company Limited, CSL Behring GmbH, BioCryst Pharmaceuticals, Inc., Pharming Group N.V., KalVista Pharmaceuticals, Inc., Akari Therapeutics plc.

Key Takeaways for Senior Decision-Makers

  • Emerging therapies such as gene therapies, extended half-life monoclonal antibodies, and oral receptor antagonists are shifting the standard of care and redefining chronic disease management.
  • Industry alliances, technology integration, and the adoption of continuous manufacturing processes are enhancing production scalability and supply chain resilience.
  • Adaptive regulatory frameworks, including real-world data submissions and conditional approvals, are expediting patient access and supporting robust evidence packages for reimbursement.
  • Patient-centric models, leveraging telemedicine and direct-to-patient services, improve treatment adherence and reduce the burden of care for diverse age groups.
  • Geographic regions vary in payer support and infrastructure, requiring flexible commercialization and access strategies that align with local regulations and market maturity levels.
  • New distribution paradigms and risk-sharing agreements are being utilized to maintain affordability and ensure sustainability amid evolving cost headwinds.

Tariff Impact on Hereditary Angioedema Supply and Innovation

In 2025, targeted tariffs on pharmaceutical raw materials and active pharmaceutical ingredients in the United States induced structural changes in supply chains for hereditary angioedema therapies. Manufacturers are responding by re-evaluating sourcing agreements, expanding domestic production, and investing in continuous manufacturing to mitigate incremental costs. These dynamics are shaping negotiations, pricing transparency, and operational strategies across the value chain while encouraging local bioprocess optimization and safeguarding patient access despite trade disruption.

Research Methodology & Data Sources

This report employs a rigorous methodology, integrating primary interviews with immunology, pharmacy, and health economics experts, alongside comprehensive secondary research from peer-reviewed literature, regulatory filings, and clinical registries. Expert panels contributed to validation, ensuring accuracy and actionable insights for hereditary angioedema market leaders.

The Importance of This Report for Strategic Planning

  • Informs evidence-based decisions leveraging segmentation, regional dynamics, and pipeline innovation for finalized go-to-market strategies.
  • Enables operational efficiency by detailing tariff-related cost risks, technology adoption, and best practices for value-based contracting.
  • Provides actionable competitive intelligence to aid alliance-building, long-term pipeline management, and proactive patient access planning.

Conclusion

The hereditary angioedema sector is advancing through strategic innovation and adaptability, extending treatment access and operational resilience. Stakeholders equipped with these insights are well positioned to unlock new value and address evolving patient and provider needs going forward.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growth of oral plasma kallikrein inhibitors improving patient adherence rates
5.2. Advancements in subcutaneous C1 esterase inhibitor formulations for home use
5.3. Emergence of gene therapy platforms targeting long-term hereditary angioedema control
5.4. Integration of digital health platforms for real-time attack monitoring and management
5.5. Increasing focus on real-world evidence studies to evaluate long-term treatment outcomes
5.6. Challenges in pricing and reimbursement for rare disease therapies affecting market access
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. HAE Treatments Market, by Therapy Mechanism
8.1. Introduction
8.2. Bradykinin Receptor Antagonist
8.2.1. Future Antagonists
8.2.1.1. Oral Receptor Antagonist
8.2.2. Icatibant
8.3. C1 Inhibitor Replacement
8.3.1. Future Mechanisms
8.3.1.1. Gene Therapy
8.3.1.2. Monoclonal Antibody Therapy
8.3.2. Plasma Derived C1 Inhibitor
8.3.3. Recombinant C1 Inhibitor
8.4. Kallikrein Inhibitor
8.4.1. Ecallantide
8.4.2. Future Catalytic Inhibitors
8.4.3. Lanadelumab
9. HAE Treatments Market, by Product Type
9.1. Introduction
9.2. Future Product Types
9.2.1. Extended Half Life Therapies
9.2.2. Long Acting Prophylactics
9.3. On Demand
9.4. Prophylactic
10. HAE Treatments Market, by Route Of Administration
10.1. Introduction
10.2. Future Routes
10.2.1. Oral
10.3. Intravenous
10.4. Subcutaneous
11. HAE Treatments Market, by Distribution Channel
11.1. Introduction
11.2. Future Channels
11.2.1. Direct To Patient
11.3. Hospital Pharmacy
11.4. Retail Pharmacy
11.5. Specialty Pharmacy
12. HAE Treatments Market, by End User
12.1. Introduction
12.2. Clinic
12.3. Future End Users
12.3.1. Telemedicine
12.4. Home Healthcare
12.5. Hospital
13. HAE Treatments Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Future Patient Groups
13.3.1. Adolescent
13.4. Geriatric
13.5. Pediatric
14. Americas HAE Treatments Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa HAE Treatments Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific HAE Treatments Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Takeda Pharmaceutical Company Limited
17.3.2. CSL Behring GmbH
17.3.3. BioCryst Pharmaceuticals, Inc.
17.3.4. Pharming Group N.V.
17.3.5. KalVista Pharmaceuticals, Inc.
17.3.6. Akari Therapeutics plc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. HAE TREATMENTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HAE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HAE TREATMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HAE TREATMENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HAE TREATMENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HAE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HAE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HAE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HAE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. HAE TREATMENTS MARKET: RESEARCHAI
FIGURE 28. HAE TREATMENTS MARKET: RESEARCHSTATISTICS
FIGURE 29. HAE TREATMENTS MARKET: RESEARCHCONTACTS
FIGURE 30. HAE TREATMENTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HAE TREATMENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HAE TREATMENTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HAE TREATMENTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HAE TREATMENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HAE TREATMENTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HAE TREATMENTS MARKET SIZE, BY ORAL RECEPTOR ANTAGONIST, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HAE TREATMENTS MARKET SIZE, BY ORAL RECEPTOR ANTAGONIST, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HAE TREATMENTS MARKET SIZE, BY ICATIBANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HAE TREATMENTS MARKET SIZE, BY ICATIBANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HAE TREATMENTS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HAE TREATMENTS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HAE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODY THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HAE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODY THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HAE TREATMENTS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HAE TREATMENTS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HAE TREATMENTS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HAE TREATMENTS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HAE TREATMENTS MARKET SIZE, BY ECALLANTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HAE TREATMENTS MARKET SIZE, BY ECALLANTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE CATALYTIC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE CATALYTIC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HAE TREATMENTS MARKET SIZE, BY LANADELUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HAE TREATMENTS MARKET SIZE, BY LANADELUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HAE TREATMENTS MARKET SIZE, BY EXTENDED HALF LIFE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HAE TREATMENTS MARKET SIZE, BY EXTENDED HALF LIFE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HAE TREATMENTS MARKET SIZE, BY LONG ACTING PROPHYLACTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HAE TREATMENTS MARKET SIZE, BY LONG ACTING PROPHYLACTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HAE TREATMENTS MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HAE TREATMENTS MARKET SIZE, BY ON DEMAND, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HAE TREATMENTS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HAE TREATMENTS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HAE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HAE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HAE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HAE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HAE TREATMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HAE TREATMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HAE TREATMENTS MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HAE TREATMENTS MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HAE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HAE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HAE TREATMENTS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HAE TREATMENTS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HAE TREATMENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HAE TREATMENTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HAE TREATMENTS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HAE TREATMENTS MARKET SIZE, BY TELEMEDICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HAE TREATMENTS MARKET SIZE, BY TELEMEDICINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HAE TREATMENTS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HAE TREATMENTS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL HAE TREATMENTS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL HAE TREATMENTS MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL HAE TREATMENTS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL HAE TREATMENTS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL HAE TREATMENTS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL HAE TREATMENTS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS HAE TREATMENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES HAE TREATMENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES HAE TREATMENTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES HAE TREATMENTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 185. CANADA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 186. CANADA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 187. CANADA HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 188. CANADA HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 189. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 190. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 191. CANADA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 192. CANADA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 193. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 194. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 195. CANADA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 196. CANADA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 197. CANADA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. CANADA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 200. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 201. CANADA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. CANADA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 204. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 205. CANADA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. CANADA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 208. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 209. CANADA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. CANADA HAE TREATMENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2018-2024 (USD MILLION)
TABLE 212. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2025-2030 (USD MILLION)
TABLE 213. CANADA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 214. CANADA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 215. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2018-2024 (USD MILLION)
TABLE 216. CANADA HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 218. MEXICO HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 219. MEXICO HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 220. MEXICO HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 221. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 224. MEXICO HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 225. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 228. MEXICO HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 229. MEXICO HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. MEXICO HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 232. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 233. MEXICO HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. MEXICO HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 236. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 237. MEXICO HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. MEXICO HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. MEXICO HAE TREATMENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2018-2024 (USD MILLION)
TABLE 244. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2025-2030 (USD MILLION)
TABLE 245. MEXICO HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. MEXICO HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2018-2024 (USD MILLION)
TABLE 248. MEXICO HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL HAE TREATMENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA HAE TREATMENTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE END USERS, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA HAE TREATMENTS MARKET SIZE, BY FUTURE PATIENT GROUPS, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2018-2024 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, 2025-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2024 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2025-2030 (USD MILLION)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2018-2024 (USD MILLION)
TABLE 322. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE MECHANISMS, 2025-2030 (USD MILLION)
TABLE 323. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2024 (USD MILLION)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2025-2030 (USD MILLION)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 326. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 327. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2018-2024 (USD MILLION)
TABLE 328. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE PRODUCT TYPES, 2025-2030 (USD MILLION)
TABLE 329. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2018-2024 (USD MILLION)
TABLE 332. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE ROUTES, 2025-2030 (USD MILLION)
TABLE 333. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 334. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 335. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2018-2024 (USD MILLION)
TABLE 336. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY FUTURE CHANNELS, 2025-2030 (USD MILLION)
TABLE 337. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 338. EUROPE, MIDDLE EAST & AFRICA HAE TREATM

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this HAE Treatments market report include:
  • Takeda Pharmaceutical Company Limited
  • CSL Behring GmbH
  • BioCryst Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • KalVista Pharmaceuticals, Inc.
  • Akari Therapeutics plc

Related Reports

Drugs for HAE Market - Global Forecast 2025-2030 - Product Image

Drugs for HAE Market - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Hereditary Angioedema Market Report and Forecast 2025-2034 - Product Image

Hereditary Angioedema Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Plasma Protease C1-inhibitor Treatment - Global Strategic Business Report - Product Image

Plasma Protease C1-inhibitor Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Hereditary Angioedema - Global Strategic Business Report - Product Image

Hereditary Angioedema - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.